ASIA-PACIFIC OPHTHALMIC DRUGS MARKET 2023-2030

Lifesciences | Pharmaceuticals

ASIA-PACIFIC OPHTHALMIC DRUGS MARKET 2023-2030

Market by Type, Market by Type, Condition, Therapeutic Type, Delivery Method, Channel, and Country Outlook | Forecast 2023-2030

Request For Customization

Request Custom Report

Request Custom Report

Enquire before buying

Enquire Before Buying

Triton’s research report examines that the Asia-Pacific ophthalmic drugs market is estimated to achieve revenue at 7.56% of CAGR during the forecast years 2023-2030.


Report scope can be customized per your requirements - Request Free Sample Report

The countries examined in this region include:

•         China

•         Japan

•         South Korea

•         India

•         ASEAN Countries

•         Australia & New Zealand

•         Rest of Asia-Pacific

The Asia-Pacific ophthalmic drugs market is undergoing a massive transformation owing to the region’s demographic shift, expansion of healthcare infrastructure, innovation, and technological advancements in the pharmaceutical industry. Additionally, the introduction of digital health services and telemedicine helps to address the accessibility issues in remote areas, thereby providing early diagnosis, delivery, and management of ophthalmic drug products for eye care treatments.  

China leads the ophthalmic drugs market with the highest share. This is due to an increase in the age-old population, their changing lifestyle patterns, eye disorders, cataracts, and diabetic retinopathy. A surge in these conditions will further lead to a wide use of ophthalmic drugs in the coming years. Moreover, innovation in ophthalmic drug development coupled with investments by pharmaceutical companies to research and develop effective eye care solutions will further drive the studied market’s growth across the nation.

Similarly, the ophthalmic drugs market has experienced pivotal growth in South Korea, primarily driven by growing awareness regarding eye health. The rising concern for eye-related disorders due to aging and long exposures to digital screens has increased the demand for these drugs. This country is also witnessing mergers and collaborations with new entrants and healthcare providers to offer an accessible variety of eye care treatment products and expand the ophthalmic drugs market.

The most commonly used and convenient ophthalmic drug is eye drops. They are a type of liquid dosage that provides targeted therapy to prevent microbial contamination and minimize the risk of irritation. In order to treat glaucoma, dry eye syndrome, allergic conjunctivitis, and bacterial conjunctivitis, eye drops are formulated and manufactured under strict aseptic conditions to ensure their sterility. The growth of the ophthalmic drugs market is determined based on type, condition, delivery method, therapeutic type, and channel. The delivery method segment is branched into gels, eye solutions and suspensions, capsules and tablets, eye drops, and ointments. 

Major market players leading in the ophthalmic drugs market include Sun Pharmaceutical Industries Ltd, AbbVie Inc, Bausch Health Companies Inc, Regeneron Pharmaceuticals Inc, Accutome Inc, Genentech Inc, Pfizer Inc, Thea Pharma Inc, Novartis AG, and Johnson & Johnson.

Sun Pharmaceutical Industries Ltd is a pharmaceutical company offering branded generics and products for treating psychiatric, nephrological, gastroenterological, heart diseases, orthopedic, neurological, and ophthalmologic diseases. The drugs are offered in several forms, like injectables, inhalers, tablets, capsules, creams, ointments, and liquids. It is headquartered in Mumbai, India and has manufacturing facilities across North America, Latin America, and Asia-Pacific.


KEY DELIVERABLES OF THE REPORT:

      Market CAGR during the forecasting years 2023-2030

      Detailed data highlighting key insights, industry components, and market strategies

      Comprehensive information and estimation of the ophthalmic drugs market revenue growth in the Asia-Pacific and its influence on the parent market

      In-depth study of forthcoming trends in consumer behavioral patterns

      A meticulous analysis of the competitive landscape, vendor scorecard, and Porter’s Five Forces

      A wide-ranging study of factors that will challenge the APAC ophthalmic drugs market’s growth during the upcoming years

Want to get specific insights? Our team of analysts can customize this report based on your preferences. Connect with us here

Related Reports

ASIA PACIFIC AESTHETIC LASER MARKET 2019-2027
Lifesciences

ASIA PACIFIC AESTHETIC LASER MARKET 2019-2027

Market By Type, Application, E ..

VIEW REPORT
ASIA PACIFIC BIOCHIPS MARKET 2019-2027
Lifesciences

ASIA PACIFIC BIOCHIPS MARKET 2019-2027

Market By Type, Substrate Mate ..

VIEW REPORT
ASIA PACIFIC BIOPSY DEVICE MARKET 2019-2027
Lifesciences

ASIA PACIFIC BIOPSY DEVICE MARKET 2019-2027

Market By Device Type, Therape ..

VIEW REPORT
ASIA PACIFIC DNA VACCINES MARKET 2019-2027
Lifesciences

ASIA PACIFIC DNA VACCINES MARKET 2019-2027

Market By Type, Application, T ..

VIEW REPORT
ASIA-PACIFIC 3D CELL CULTURE MARKET 2019-2027
Lifesciences

ASIA-PACIFIC 3D CELL CULTURE MARKET 2019-2027

Market By Technology, Applicat ..

VIEW REPORT
ASIA-PACIFIC AIRWAY CLEARANCE SYSTEM MARKET 2019-2028
Lifesciences

ASIA-PACIFIC AIRWAY CLEARANCE SYSTEM MARKET 2019-2028

Market By Application, Type, E ..

VIEW REPORT
ASIA-PACIFIC AMNIOTIC MEMBRANE MARKET 2022-2028
Lifesciences

ASIA-PACIFIC AMNIOTIC MEMBRANE MARKET 2022-2028

Market by Type, Application, E ..

VIEW REPORT

Table of Content

1. ASIA-PACIFIC OPHTHALMIC DRUGS MARKET - SUMMARY

2. INDUSTRY OUTLOOK

2.1. TECHNOLOGY SNAPSHOT

2.2. IMPACT ANALYSIS ON THE OPHTHALMIC DRUGS MARKET

2.2.1. COVID-19 IMPACT ON THE OPHTHALMIC DRUGS MARKET

2.3. PORTER’S FIVE FORCES ANALYSIS

2.3.1. THREAT OF NEW ENTRANTS

2.3.2. THREAT OF SUBSTITUTES

2.3.3. BARGAINING POWER OF BUYERS

2.3.4. BARGAINING POWER OF SUPPLIERS

2.3.5. THREAT OF COMPETITIVE RIVALRY

2.4. MARKET MATURITY ANALYSIS

2.5. REGULATORY FRAMEWORK

2.6. KEY BUYING IMPACT ANALYSIS

2.7. KEY MARKET STRATEGIES

2.7.1. COLLABORATIONS

2.7.2. PRODUCT LAUNCHES

2.7.3. MERGERS & ACQUISITIONS

2.8. MARKET DRIVERS

2.8.1. AGING POPULATION VULNERABLE TO EYE DISORDERS

2.8.2. PROGRESS IN DRUG DELIVERY TECHNOLOGIES

2.8.3. ESCALATING INCIDENCE OF OCULAR DISEASES

2.8.4. REIMBURSEMENT POLICIES BY HEALTHCARE SYSTEMS

2.9. MARKET CHALLENGES

2.9.1. CHALLENGING TIMELINES FOR PRODUCT APPROVAL

2.9.2. ADVERSE EFFECTS ASSOCIATED WITH OPHTHALMIC DRUG USAGE

2.10. MARKET OPPORTUNITIES

2.10.1. SURGE IN INTEREST REGARDING TOPICALLY ADMINISTERED OPHTHALMIC DRUGS 

2.10.2. INCREASE IN APPROVALS FOR INNOVATIVE OPHTHALMIC THERAPIES

2.11. ANALYST PERSPECTIVE

3. ASIA-PACIFIC OPHTHALMIC DRUGS MARKET – BY TYPE

3.1. PRESCRIPTION DRUGS

3.2. OVER-THE-COUNTER DRUGS

4. ASIA-PACIFIC OPHTHALMIC DRUGS MARKET – BY CONDITION

4.1. DRY EYE

4.2. GLAUCOMA

4.3. INFECTION/INFLAMMATION/ALLERGIES

4.4. RETINAL DISORDER

4.4.1. WET-AGE RELATED MACULAR DEGENERATION

4.4.2. DRY-AGE RELATED MACULAR DEGENERATION

4.4.3. DIABETIC RETINOPATHY

4.4.4. OTHER RETINAL DISORDERS

4.5. OTHER CONDITIONS

5. ASIA-PACIFIC OPHTHALMIC DRUGS MARKET – BY THERAPEUTIC TYPE

5.1. ANTI-GLAUCOMA

5.2. ANTI-INFECTION

5.3. ANTI-INFLAMMATORY

5.4. ANTI-ALLERGY

5.5. OTHER THERAPEUTIC TYPES

6. ASIA-PACIFIC OPHTHALMIC DRUGS MARKET – BY DELIVERY METHOD

6.1. GELS

6.2. EYE SOLUTIONS & SUSPENSIONS

6.3. CAPSULES & TABLETS

6.4. EYE DROPS

6.5. OINTMENTS

7. ASIA-PACIFIC OPHTHALMIC DRUGS MARKET – BY CHANNEL

7.1. HOSPITAL PHARMACIES

7.2. DRUG STORES

7.3. ONLINE PHARMACIES

7.4. OTHER CHANNELS

8. ASIA-PACIFIC OPHTHALMIC DRUGS MARKET – COUNTRY OUTLOOK

8.1. CHINA

8.1.1. CHINA OPHTHALMIC DRUGS MARKET FORECAST & PROSPECTS

8.2. JAPAN

8.2.1. JAPAN OPHTHALMIC DRUGS MARKET FORECAST & PROSPECTS

8.3. INDIA

8.3.1. INDIA OPHTHALMIC DRUGS MARKET FORECAST & PROSPECTS

8.4. SOUTH KOREA

8.4.1. SOUTH KOREA OPHTHALMIC DRUGS MARKET FORECAST & PROSPECTS

8.5. ASEAN COUNTRIES

8.5.1. ASEAN COUNTRIES OPHTHALMIC DRUGS MARKET FORECAST & PROSPECTS

8.6. AUSTRALIA & NEW ZEALAND

8.6.1. AUSTRALIA & NEW ZEALAND OPHTHALMIC DRUGS MARKET FORECAST & PROSPECTS

8.7. REST OF ASIA-PACIFIC

8.7.1. REST OF ASIA-PACIFIC OPHTHALMIC DRUGS MARKET FORECAST & PROSPECTS

9. COMPETITIVE LANDSCAPE

9.1. ABBVIE INC

9.1.1. OVERVIEW

9.1.2. PRODUCT PORTFOLIO

9.1.3. KEY STRENGTHS

9.1.4. KEY CHALLENGES

9.2. BAUSCH HEALTH COMPANIES INC

9.2.1. OVERVIEW

9.2.2. PRODUCT PORTFOLIO

9.2.3. KEY STRENGTHS

9.2.4. KEY CHALLENGES

9.3. JOHNSON & JOHNSON

9.3.1. OVERVIEW

9.3.2. PRODUCT PORTFOLIO

9.3.3. KEY STRENGTHS

9.3.4. KEY CHALLENGES

9.4. NOVARTIS AG

9.4.1. OVERVIEW

9.4.2. PRODUCT PORTFOLIO

9.4.3. KEY STRENGTHS

9.4.4. KEY CHALLENGES

9.5. REGENERON PHARMACEUTICALS INC

9.5.1. OVERVIEW

9.5.2. PRODUCT PORTFOLIO

9.5.3. KEY STRENGTHS

9.5.4. KEY CHALLENGES

9.6. SUN PHARMACEUTICAL INDUSTRIES LTD

9.6.1. OVERVIEW

9.6.2. PRODUCT PORTFOLIO

9.6.3. KEY STRENGTHS

9.6.4. KEY CHALLENGES

9.7. ACCUTOME INC

9.7.1. OVERVIEW

9.7.2. PRODUCT PORTFOLIO

9.7.3. KEY STRENGTHS

9.7.4. KEY CHALLENGES

9.8. GENENTECH INC

9.8.1. OVERVIEW

9.8.2. PRODUCT PORTFOLIO

9.8.3. KEY STRENGTHS

9.8.4. KEY CHALLENGES

9.9. THEA PHARMA INC

9.9.1. OVERVIEW

9.9.2. PRODUCT PORTFOLIO

9.9.3. KEY STRENGTHS

9.9.4. KEY CHALLENGES

9.10. PFIZER INC

9.10.1. OVERVIEW

9.10.2. PRODUCT PORTFOLIO

9.10.3. KEY STRENGTHS

9.10.4. KEY CHALLENGES

10. RESEARCH METHODOLOGY & SCOPE

10.1. RESEARCH SCOPE & DELIVERABLES

10.2. SOURCES OF DATA

10.3. RESEARCH METHODOLOGY

List of Tables

TABLE 1: ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY COUNTRY, 2023-2030 (IN $ MILLION)

TABLE 2: REGULATORY FRAMEWORK

TABLE 3: LIST OF COLLABORATIONS

TABLE 4: LIST OF PRODUCT LAUNCHES

TABLE 5: LIST OF MERGERS & ACQUISITIONS

TABLE 6: ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY COUNTRY OUTLOOK, 2023-2030 (IN $ MILLION)

TABLE 7: ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY TYPE, 2023-2030 (IN $ MILLION)

TABLE 8: ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY CONDITION, 2023-2030 (IN $ MILLION)

TABLE 9: ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY RETINAL DISORDER, 2023-2030 (IN $ MILLION)

TABLE 10: ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC TYPE, 2023-2030 (IN $ MILLION)

TABLE 11: ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY DELIVERY METHOD, 2023-2030 (IN $ MILLION)

TABLE 12: ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY CHANNEL, 2023-2030 (IN $ MILLION)

List of Figures

FIGURE 1: TECHNOLOGY SNAPSHOT

FIGURE 2: MARKET MATURITY ANALYSIS

FIGURE 3: ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY TYPE, 2022 & 2030 (IN %)

FIGURE 4: ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY PRESCRIPTION DRUGS, 2023-2030 (IN $ MILLION)

FIGURE 5: ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY OVER-THE-COUNTER DRUGS, 2023-2030 (IN $ MILLION)

FIGURE 6: ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY CONDITION, 2022 & 2030 (IN %)

FIGURE 7: ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY DRY EYE, 2023-2030 (IN $ MILLION)

FIGURE 8: ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY GLAUCOMA, 2023-2030 (IN $ MILLION)

FIGURE 9: ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY INFECTION/INFLAMMATION/ALLERGIES, 2023-2030 (IN $ MILLION)

FIGURE 10: ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY RETINAL DISORDER, 2023-2030 (IN $ MILLION)

FIGURE 11: ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY RETINAL DISORDER, 2022 & 2030 (IN %)

FIGURE 12: ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY WET AGE-RELATED MACULAR DEGENERATION, 2023-2030 (IN $ MILLION)

FIGURE 13: ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY DRY AGE-RELATED MACULAR DEGENERATION, 2023-2030 (IN $ MILLION)

FIGURE 14: ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY DIABETIC RETINOPATHY, 2023-2030 (IN $ MILLION)

FIGURE 15: ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY OTHER RETINAL DISORDERS, 2023-2030 (IN $ MILLION)

FIGURE 16: ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY OTHER CONDITIONS, 2023-2030 (IN $ MILLION)

FIGURE 17: ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY THERAPEUTIC TYPE, 2022 & 2030 (IN %)

FIGURE 18: ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY ANTI-GLAUCOMA, 2023-2030 (IN $ MILLION)

FIGURE 19: ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY ANTI-INFECTION, 2023-2030 (IN $ MILLION)

FIGURE 20: ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY ANTI-INFLAMMATORY, 2023-2030 (IN $ MILLION)

FIGURE 21: ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY ANTI-ALLERGY, 2023-2030 (IN $ MILLION)

FIGURE 22: ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY OTHER THERAPEUTIC TYPES, 2023-2030 (IN $ MILLION)

FIGURE 23: ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY DELIVERY METHOD, 2022 & 2030 (IN %)

FIGURE 24: ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY GELS, 2023-2030 (IN $ MILLION)

FIGURE 25: ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY EYE SOLUTIONS & SUSPENSIONS, 2023-2030 (IN $ MILLION)

FIGURE 26: ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY CAPSULES & TABLETS, 2023-2030 (IN $ MILLION)

FIGURE 27: ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY EYE DROPS, 2023-2030 (IN $ MILLION)

FIGURE 28: ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY OINTMENTS, 2023-2030 (IN $ MILLION)

FIGURE 29: ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY CHANNEL, 2022 & 2030 (IN %)

FIGURE 30: ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY HOSPITAL PHARMACIES, 2023-2030 (IN $ MILLION)

FIGURE 31: ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY DRUG STORES, 2023-2030 (IN $ MILLION)

FIGURE 32: ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY ONLINE PHARMACIES, 2023-2030 (IN $ MILLION)

FIGURE 33: ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY OTHER CHANNELS, 2023-2030 (IN $ MILLION)

FIGURE 34: ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, BY COUNTRY OUTLOOK, 2022 & 2030 (IN %)

FIGURE 35: CHINA OPHTHALMIC DRUGS MARKET, 2023-2030 (IN $ MILLION)

FIGURE 36: JAPAN OPHTHALMIC DRUGS MARKET, 2023-2030 (IN $ MILLION)

FIGURE 37: INDIA OPHTHALMIC DRUGS MARKET, 2023-2030 (IN $ MILLION)

FIGURE 38: SOUTH KOREA OPHTHALMIC DRUGS MARKET, 2023-2030 (IN $ MILLION)

FIGURE 39: ASEAN COUNTRIES OPHTHALMIC DRUGS MARKET, 2023-2030 (IN $ MILLION)

FIGURE 40: AUSTRALIA & NEW ZEALAND OPHTHALMIC DRUGS MARKET, 2023-2030 (IN $ MILLION)

FIGURE 41: REST OF ASIA-PACIFIC OPHTHALMIC DRUGS MARKET, 2023-2030 (IN $ MILLION)

Purchase Options

  • Licence Type
  • Price
  • User/Sharing
  • Printing
  • Delivery Formats
  • Free customization (Pre-sale)
  • Analyst hour support (Post Sale)
  • Customized notification for newly published report
  • Free report on update (within 180 days)

Single User PDF

$1,500.00

  • User/Sharing
  • Restricted to one authorized user
  • Printing
  • Not printable
  • Delivery Formats
  • Pdf
  • Free customization (Pre-sale)
  • 10% Free customization
  • Analyst hour support (Post Sale)
  • 3 hours
  • Customized notification (newly published)
  • Free report on update (within 180 days)

Enterprise Online/PDF

$2,200.00

  • User/Sharing
  • Unlimited
  • Printing
  • Unlimited
  • Delivery Formats
  • Pdf and market estimation excel
  • Free customization (Pre-sale)
  • 20% Free customization
  • Analyst hour support (Post Sale)
  • 8 hour
  • Customized notification (newly published)
  • Free report on update (within 180 days)

Request free Sample

Request Custom Report

Request Custom Report

Enquire before buying

Enquire Before Buying